Emergent BioSolutions (EBS) Current Assets (2010 - 2026)

Emergent BioSolutions' Current Assets history runs 17 years deep, the most recent figure standing at $637.6 million for Q1 2026.

• On a quarterly basis, Current Assets fell 9.79% year-over-year to $637.6 million in Q1 2026; TTM through Mar 2026 was $637.6 million, a 9.79% decrease from a year earlier, with the FY2025 full-year figure at $662.5 million, up 10.66% from the prior year.
• Current Assets eased to $637.6 million in Q1 2026 per EBS's latest filing, from $662.5 million in the prior quarter.
• Across five years, Current Assets topped out at $1.2 billion in Q1 2023 and bottomed at $598.7 million in Q4 2024.
• The 5-year median for Current Assets is $719.5 million (2025), against an average of $823.7 million.
• Across the five-year window, Current Assets plunged 44.13% in 2024 and rose 18.97% in 2025, its largest moves.
• Year by year, Current Assets stood at $1.2 billion in 2022, then tumbled by 43.86% to $679.5 million in 2023, then retreated by 11.89% to $598.7 million in 2024, then advanced by 10.66% to $662.5 million in 2025, then retreated by 3.76% to $637.6 million in 2026.
• Per Business Quant, the three latest EBS Current Assets figures stand at $637.6 million (Q1 2026), $662.5 million (Q4 2025), and $786.9 million (Q3 2025).